CoChat
Sign Up
Cited by 9MicroRNA in disease regulationCancer-related molecular mechanisms researchGlioma Diagnosis and Treatment

MicroRNA‑505‑3p inhibits development of glioma by targeting HMGB1 and regulating AKT expression

Open access
Cheng, Zhenlin, Wang, Bin, Zhang, Cheng·2020·Oncology Letters
DOI 10.3892/ol.2020.11714PMC PMC7377041
Open this paper in CoChat — free accountOpen PDF

Abstract

Previous studies have reported that microRNA (miR)-505 exhibits important effect in human cancers. However, the regulatory mechanism of miR-505-3p/high-mobility group box 1 (HMGB1) axis is still unclear in glioma. Therefore, the regulatory mechanism of miR-505-3p/HMGB1 axis in glioma was illuminated. Expression of miR-505-3p and HMGB1 was observed by RT-qPCR. Protein expression was measured by western blot analysis. Dual luciferase assay was performed to confirm the relationship between miR-505-3p and HMGB1. The function of miR-505-3p was investigated by MTT and Transwell assays. Expression of miR-505-3p was reduced in glioma, which was related to poor clinical outcomes and prognosis in glioma patients. Moreover, overexpression of miR-505-3p suppressed proliferation, migration and invasion of glioma cells. In addition, HMGB1 was confirmed as a direct target of miR-505-3p, and miR-505-3p inhibited the development of glioma by targeting HMGB1. Furthermore, miR-505-3p blocked EMT suppressing p-AKT expression in glioma cells. In conclusion, miR-505-3p inhibited the development of glioma by targeting HMGB1 and regulating AKT expression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ol.2020.11714

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The expression level of miR-505-3p is reduced in human GBM tissues and cell lines compared to control groups.

    “The expression level of miR-505-3p is reduced in human GBM tissues and cell lines compared to control groups (18).”

    From Functional interaction between miR-505-3p and miR-21 contributes to GBM suppression (2026) · cites this paper as [18]

    The Results (page unavailable) report reduced miR-505-3p in 44 glioma tissues versus normal tissues and in U251, A172, and LN229 cells versus normal human astrocytes. The Patients and methods section (page unavailable) shows that the tissue cohort included low- and high-grade gliomas, so the tissue finding is not established specifically for GBM. (LLM, conf=0.89)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 31

  1. [1]Omuro A DeAngelis LM Glioblastoma and other malignant gliomas: A clinical review JAMA 310 1842 1850 2013 10.1001/jama.2013.280319 24193082 · DOI
  2. [2]Zeng T Cui D Gao L Glioma: An overview of current classifications, characteristics, molecular biology and target therapies Front Biosci 20 1104 1115 2015 10.2741/4362 25961548 · DOI
  3. [3]Ostrom QT Gittleman H Stetson L Virk S Barnholtz-Sloan JS Epidemiology of intracranial gliomas Prog Neurol Surg 30 1 11 2018 10.1159/000464374 29241168 · DOI
  4. [4]Qaddoumi I Sultan I Gajjar A Outcome and prognostic features in pediatric gliomas: A review of 6212 cases from the Surveillance, Epidemiology, and End Results database Cancer 115 5761 5770 2009 10.1002/cncr.24663 19813274 PMC2794938 · DOI
  5. [5]Bartel DP MicroRNAs: Genomics, biogenesis, mechanism, and function Cell 116 281 297 2004 10.1016/S0092-8674(04)00045-5 14744438 · DOI
  6. [6]Wu Q Xu L Wang C Fan W Yan H Li Q MicroRNA-124-3p represses cell growth and cell motility by targeting EphA2 in glioma Biochem Biophys Res Commun 503 2436 2442 2018 10.1016/j.bbrc.2018.06.173 29969628 · DOI
  7. [7]Wang BQ Yang B Yang HC Wang JY Hu S Gao YS Bu XY MicroRNA-499a decelerates glioma cell proliferation while accelerating apoptosis through the suppression of Notch1 and the MAPK signaling pathway Brain Res Bull 142 96 106 2018 10.1016/j.brainresbull.2018.06.005 29908894 · DOI
  8. [8]Xu J He J Huang H Peng R Xi J MicroRNA-423-3p promotes glioma growth by targeting PANX2 Oncol Lett 16 179 188 2018 29928399 PMC6006452
  9. [9]Ramachandran SS Muiwo P Ahmad HM Pandey RM Singh S Bakhshi S Kumar L Bhattacharya A Gupta YK miR-505-5p and miR-193b-3p: Potential biomarkers of imatinib response in patients with chronic myeloid leukemia Leuk Lymphoma 58 1981 1984 2017 10.1080/10428194.2016.1272681 28093001 · DOI
  10. [10]Yang Q Jia C Wang P Xiong M Cui J Li L Wang W Wu Q Chen Y Zhang T MicroRNA-505 identified from patients with essential hypertension impairs endothelial cell migration and tube formation Int J Cardiol 177 925 934 2014 10.1016/j.ijcard.2014.09.204 25449503 · DOI
  11. [11]Qin Z He W Tang J Ye Q Dang W Lu Y Wang J Li G Yan Q Ma J MicroRNAs orovide feedback regulation of epithelial-mesenchymal transition induced by growth factors J Cell Physiol 231 120 129 2016 10.1002/jcp.25060 26032086 · DOI
  12. [12]Ding J Cui X Liu Q Emerging role of HMGB1 in lung diseases: Friend or foe J Cell Mol Med 21 1046 1057 2017 10.1111/jcmm.13048 28039939 PMC5431121 · DOI
  13. [13]Liu PL Tsai JR Hwang JJ Chou SH Cheng YJ Lin FY Chen YL Hung CY Chen WC Chen YH High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness Am J Respir Cell Mol Biol 43 530 538 2010 10.1165/rcmb.2009-0269OC 19933377 · DOI
  14. [14]Song B Song WG Li ZJ Xu ZF Wang XW Wang CX Liu J Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC-803 gastric cancer cells Cell Biochem Funct 30 11 17 2012 10.1002/cbf.1811 21953494 · DOI
  15. [15]Yao X Zhao G Yang H Hong X Bie L Liu G Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma J Cancer Res Clin Oncol 136 677 684 2010 10.1007/s00432-009-0706-1 19898867 PMC11917171 · DOI
  16. [16]Pan C Wang Y Qiu MK Wang SQ Liu YB Quan ZW Ou JM Knockdown of HMGB1 inhibits cell proliferation and induces apoptosis in hemangioma via downregulation of AKT pathway J Biol Regul Homeost Agents 31 41 49 2017 28337869
  17. [17]Zhang J Zhang J Qiu W Zhang J Li Y Kong E Lu A Xu J Lu X MicroRNA-1231 exerts a tumor suppressor role through regulating the EGFR/PI3K/AKT axis in glioma J Neurooncol 139 547 562 2018 10.1007/s11060-018-2903-8 29774498 PMC6132976 · DOI
  18. [18]Livak KJ Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method Methods 25 402 408 2001 10.1006/meth.2001.1262 11846609 · DOI · Paper page
  19. [19]Ma C Wei F Xia H Liu H Dong X Zhang Y Luo Q Liu Y Li Y MicroRNA-10b mediates TGF-β1-regulated glioblastoma proliferation, migration and epithelial-mesenchymal transition Int J Oncol 50 1739 1748 2017 10.3892/ijo.2017.3947 28393237 · DOI
  20. [20]Jiang Y Wang X Zhang J Lai R MicroRNA-599 suppresses glioma progression by targeting RAB27B Oncol Lett 16 1243 1252 2018 29963197 PMC6019909
  21. [21]Zhang C Yang X Fu C Liu X Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway Gene 672 172 179 2018 10.1016/j.gene.2018.06.030 29906532 · DOI · Paper page
  22. [22]Ma C Xu B Husaiyin S Wang L Wusainahong K Ma J Zhu K Niyazi M MicroRNA-505 predicts prognosis and acts as tumor inhibitor in cervical carcinoma with inverse association with FZD4 Biomed Pharmacother 92 586 594 2017 10.1016/j.biopha.2017.04.028 28577497 · DOI
  23. [23]Liu YJ Li W Chang F Liu JN Lin JX Chen DX MicroRNA-505 is downregulated in human osteosarcoma and regulates cell proliferation, migration and invasion Oncol Rep 39 491 500 2018 29251324 PMC5783616
  24. [24]Lu L Qiu C Li D Bai G Liang J Yang Q MicroRNA-505 suppresses proliferation and invasion in hepatoma cells by directly targeting high-mobility group box 1 Life Sci 157 12 18 2016 10.1016/j.lfs.2016.05.039 27259809 · DOI
  25. [25]Stoetzer OJ Fersching DM Salat C Steinkohl O Gabka CJ Hamann U Braun M Feller AM Heinemann V Siegele B Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy Tumour Biol 34 81 90 2013 10.1007/s13277-012-0513-1 22983919 · DOI
  26. [26]Meng Q Zhao J Liu H Zhou G Zhang W Xu X Zheng M HMGB1 promotes cellular proliferation and invasion, suppresses cellular apoptosis in osteosarcoma Tumour Biol 35 12265 12274 2014 10.1007/s13277-014-2535-3 25168370 · DOI
  27. [27]Zhang J Liu C Hou R Knockdown of HMGB1 improves apoptosis and suppresses proliferation and invasion of glioma cells Chin J Cancer Res 26 658 668 2014 25561763 PMC4279198
  28. [28]Wang XJ Zhou SL Fu XD Zhang YY Liang B Shou JX Wang JY Ma J Clinical and prognostic significance of high-mobility group box-1 in human gliomas Exp Ther Med 9 513 518 2015 10.3892/etm.2014.2089 25574225 PMC4280992 · DOI
  29. [29]Lu L Zhang D Xu Y Bai G Lv Y Liang J miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1 Biomed Pharmacother 104 613 621 2018 10.1016/j.biopha.2018.05.087 29803174 · DOI
  30. [30]Fresno Vara JA Casado E de Castro J Cejas P Belda-Iniesta C González-Barón M PI3K/Akt signalling pathway and cancer Cancer Treat Rev 30 193 204 2004 10.1016/j.ctrv.2003.07.007 15023437 · DOI
  31. [31]Rathod SS Rani SB Khan M Muzumdar D Shiras A Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways FEBS Open Bio 4 485 495 2014 10.1016/j.fob.2014.05.002 24944883 PMC4060015 · DOI

Cited by

Sorted by citations

Authors
Cheng, Z., Wang, B., & Zhang, C.
Affiliations
  • Hexi University (CN)
  • People's Hospital of Xinjiang Uygur Autonomous Region (CN)
Corresponding author
Zhang, Cheng
ORCID
Venue
Oncology Letters
Publisher
Spandidos Publications
Published
2020-06-09
Volume
20
Issue
2
Pages
1663-1670
ISSN
  • 1792-1074 (ISSN-L)
  • 1792-1082
DOI
10.3892/ol.2020.11714
PMC
PMC7377041
OpenAlex
W3034885278
Cited by
9
References
0
Citations by year
2026: 1 · 2024: 4 · 2023: 3 · 2022: 1
FWCI
0.34
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Oncology Letters (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
Keywords
HMGB1, Akt, glioma, epithelial-mesenchymal transition, tumor cell proliferation, cell migration and invasion, microRNA target regulation, prognosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review